MONARCH 2 Phase 3 trial

October 4, 2019October 7, 2019

Verzenio-Faslodex Combo Prolongs Survival of Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer who had been treated previously with endocrine therapy, a Phase ... Read more

August 2, 2019

Verzenio-Faslodex Combo Prolongs Survival in Advanced Breast Cancer, Interim Phase 3 Data Show

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative advanced or metastatic breast cancer who had been previously treated with endocrine therapy, interim analysis ... Read more

March 23, 2017March 23, 2017

Abemaciclib-Faslodex Combo Increases Progression-free Survival in Advanced Breast Cancer

News

Adding the CDK4/6 inhibitor abemaciclib to Faslodex (fulvestrant) is a promising way to treat patients with an advanced breast cancer who experienced a relapse or had their disease progress after ... Read more